Acumen Pharmaceuticals publishes corporate presentation on sabirnetug (ACU193) Phase 2 program for early Alzheimer’s disease

Reuters

Mar 16

Acumen Pharmaceuticals publishes corporate presentation on sabirnetug (ACU193) Phase 2 program for early Alzheimer’s disease

Acumen said sabirnetug (ACU193), a monoclonal antibody designed to selectively target toxic amyloid beta oligomers, remains in a fully enrolled global Phase 2 intravenous study in early Alzheimer’s disease, with topline results expected in late 2026. The company also cited an Enhanced Brain Delivery program combining a TfR brain transporter with an anti-amyloid beta oligomer antibody, with an IND targeted for mid-2027. Acumen reported cash, cash equivalents and marketable securities of USD 136 million as of Sept. 30, 2025, and said it expects its cash runway to extend into early 2027. It also referenced Phase 1 data for sabirnetug in early Alzheimer’s patients that included 5 total cases of ARIA-E, or about 10%. A related Phase 1 study is cited as INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief on March 16, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2619454168"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2619454168\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2619454168?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 18:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619454168","market":"us","top_or_hot":-1,"title":"Acumen Pharmaceuticals publishes corporate presentation on sabirnetug (ACU193) Phase 2 program for early Alzheimer’s disease","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Acumen Pharmaceuticals publishes corporate presentation on sabirnetug (ACU193) Phase 2 program for early Alzheimer’s disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Acumen said sabirnetug (ACU193), a monoclonal antibody designed to selectively target toxic amyloid beta oligomers, remains in a fully enrolled global Phase 2 intravenous study in early Alzheimer’s disease, with topline results expected in late 2026. The company also cited an Enhanced Brain Delivery program combining a TfR brain transporter with an anti-amyloid beta oligomer antibody, with an IND targeted for mid-2027. Acumen reported cash, cash equivalents and marketable securities of USD 136 million as of Sept. 30, 2025, and said it expects its cash runway to extend into early 2027. It also referenced Phase 1 data for sabirnetug in early Alzheimer’s patients that included 5 total cases of ARIA-E, or about 10%. A related Phase 1 study is cited as INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief on March 16, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acumen Pharmaceuticals publishes corporate presentation on sabirnetug (ACU193) Phase 2 program for early Alzheimer’s disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcumen Pharmaceuticals publishes corporate presentation on sabirnetug (ACU193) Phase 2 program for early Alzheimer’s disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-16 18:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Acumen Pharmaceuticals publishes corporate presentation on sabirnetug (ACU193) Phase 2 program for early Alzheimer’s disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Acumen said sabirnetug (ACU193), a monoclonal antibody designed to selectively target toxic amyloid beta oligomers, remains in a fully enrolled global Phase 2 intravenous study in early Alzheimer’s disease, with topline results expected in late 2026. The company also cited an Enhanced Brain Delivery program combining a TfR brain transporter with an anti-amyloid beta oligomer antibody, with an IND targeted for mid-2027. Acumen reported cash, cash equivalents and marketable securities of USD 136 million as of Sept. 30, 2025, and said it expects its cash runway to extend into early 2027. It also referenced Phase 1 data for sabirnetug in early Alzheimer’s patients that included 5 total cases of ARIA-E, or about 10%. A related Phase 1 study is cited as INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief on March 16, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABOS","symbol_name":"Acumen Pharmaceuticals, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDLNtyD0:1","article_id":"2619454168","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619454168","pubTimestamp":1773657784,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Acumen said sabirnetug , a monoclonal antibody designed to selectively target toxic amyloid beta oligomers, remains in a fully enrolled global Phase 2 intravenous study in early Alzheimer’s disease, with topline results expected in late 2026. The company also cited an Enhanced Brain Delivery program combining a TfR brain transporter with an anti-amyloid beta oligomer antibody, with an IND targeted for mid-2027. Acumen reported cash, cash equivalents and marketable securities of USD 136 million as of Sept. 30, 2025, and said it expects its cash runway to extend into early 2027. It also referenced Phase 1 data for sabirnetug in early Alzheimer’s patients that included 5 total cases of ARIA-E, or about 10%. A related Phase 1 study is cited as INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABOS":"Acumen Pharmaceuticals, Inc.","BK4139":"生物科技","BK4539":"次新股"},"translate_title":"Acumen Pharmaceuticals发布关于sabirnetug(ACU193)早期阿尔茨海默病2期项目的公司演示文稿","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABOS":0.9},"content_text":"Acumen Pharmaceuticals publishes corporate presentation on sabirnetug (ACU193) Phase 2 program for early Alzheimer’s disease\n    \n\n        Acumen said sabirnetug (ACU193), a monoclonal antibody designed to selectively target toxic amyloid beta oligomers, remains in a fully enrolled global Phase 2 intravenous study in early Alzheimer’s disease, with topline results expected in late 2026. The company also cited an Enhanced Brain Delivery program combining a TfR brain transporter with an anti-amyloid beta oligomer antibody, with an IND targeted for mid-2027. Acumen reported cash, cash equivalents and marketable securities of USD 136 million as of Sept. 30, 2025, and said it expects its cash runway to extend into early 2027. It also referenced Phase 1 data for sabirnetug in early Alzheimer’s patients that included 5 total cases of ARIA-E, or about 10%. A related Phase 1 study is cited as INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief on March 16, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}